Hammarskiöld advised Carnegie Investment Bank, ABG Sundal Collier, DNB Markets and Kempen Co N.V. (Joint Bookrunners) in connection with the directed share issue in Wilson Therapeutics AB (publ) of approximately SEK 244 million.
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease.
Hammarskiöld's team consisted of:
Carl-Johan Pousette (Partner)
Magnus Möller (On extended leave for court service)
